Filing Details

Accession Number:
0001213900-21-014917
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-11 17:50:30
Reporting Period:
2021-03-09
Accepted Time:
2021-03-11 17:50:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1553643 Relmada Therapeutics Inc. RLMD Pharmaceutical Preparations (2834) 455401931
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1658544 Edward Paul Kelly C/O Relmada Therapeutics, Inc.
880 Third Avenue, 12Th Floor
New York NY 10022
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-09 5,000 $3.24 172,295 No 4 M Direct
Common Stock Disposition 2021-03-09 3,388 $35.42 168,907 No 4 S Direct
Common Stock Disposition 2021-03-09 1,612 $36.33 167,295 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Options to purchase common stock Disposition 2021-03-09 5,000 $0.00 5,000 $3.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
50,500 2017-10-20 2027-10-20 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.
  2. The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
  3. Sales prices range from $35.00 to $35.94 per share, inclusive.
  4. Sales prices range from $36.07 to $36.55 per share, inclusive.
  5. The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.
  6. Not applicable.